Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Capecitabine + HX008 + Oxaliplatin |
Indication/Tumor Type | gastroesophageal junction adenocarcinoma |
Response Type | not predictive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | gastroesophageal junction adenocarcinoma | not predictive | Capecitabine + HX008 + Oxaliplatin | Phase I | Actionable | In a Phase Ib trial, treatment with HX008, Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination therapy resulted in an objective response rate (ORR) of 75% (9/12) and disease control rate (DCR) of 83.3% (10/12) in CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients, compared to an ORR and DCR of 66.7% (6/9) and 100% (9/9) respectively in CD274 (PD-L1)-negative patients; however, no difference was observed in progression-free survival (p=0.19) (PMID: 33457083). | 33457083 |
PubMed Id | Reference Title | Details |
---|---|---|
(33457083) | Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. | Full reference... |